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A B S T R A C T
Antiretroviral-releasing vaginal rings are at the forefront of ongoing eﬀorts to develop microbicide-based stra-
tegies for prevention of heterosexual transmission of the human immunodeﬁciency virus (HIV). However, tra-
ditional ring designs are generally only useful for vaginal administration of relatively potent, lipophilic, and
small molecular weight drug molecules that have suﬃcient permeability in the non-biodegradable silicone
elastomer or thermoplastic polymers. Here, we report a novel, easy-to-manufacture ‘exposed-core’ vaginal ring
that provides sustained release of the protein microbicide candidate 5P12-RANTES, an experimental chemokine
analogue that potently blocks the HIV CCR5 coreceptor. In vitro release, mechanical, and stability testing de-
monstrated the utility and practicality of this novel ring design. In a sheep pharmacokinetic model, a ring
containing two ¼-length excipient-modiﬁed silicone elastomer cores – each containing lyophilised 5P12-
RANTES and exposed to the external environment by two large windows – provided sustained concentrations of
5P12-RANTES in vaginal ﬂuid and vaginal tissue between 10 and 10,000 ng/g over 28days, at least 50 and up to
50,000 times the reported in vitro IC50 value.
1. Introduction
Vaginal rings for controlled release of drug substances to the human
vagina were ﬁrst described in 1970 [1–3] following earlier reports
demonstrating drug permeation through polysiloxane tubes when im-
planted in the ventricular myocardium of dogs [4,5], subdermally in
ewes [6] and subdermally in rats [7]. Seven vaginal ring products have
since reached market, ﬁve of which are fabricated from silicone elas-
tomers (Estring®, Femring®, Progering®, Fertiring® and Annovera®) and
two from thermoplastic polymers (Nuvaring® and Ornibel®) (Table 1).
Also, an antiretroviral-releasing silicone elastomer vaginal ring for HIV
prevention is presently under review by the European Medicines
Agency [8,9], while various other drug-releasing ring devices are un-
dergoing clinical testing (Table 1). The active pharmaceutical in-
gredients in these vaginal ring products are all highly potent, small
molecular weight (< 540 g/mol), lipophilic (log P > 2) steroids or
antiviral molecules (Table 1, Fig. 1) that can readily permeate the hy-
drophobic silicone elastomers and thermoplastic polymers to oﬀer
clinically signiﬁcant release rates. In general, for molecules having
physicochemical characteristics outside the limits deﬁned by the da-
shed box in Fig. 1, conventional ring designs and/or polymeric mate-
rials are usually not practical due to signiﬁcant constraints in drug
permeability [10,11].
There is considerable interest in developing new vaginal ring de-
signs for sustained or controlled release of large molecular weight and/
or hydrophilic drug molecules, and especially therapeutic peptides,
proteins, antibodies, and nucleic acids. Much of the innovation in va-
ginal ring design during recent years has been driven by eﬀorts to de-
velop microbicidal vaginal rings for prevention of sexual transmission
of the human immunodeﬁciency virus (HIV) and multipurpose pre-
vention technology (MPT) rings for simultaneous prevention of HIV,
pregnancy, and/or sexually transmitted infections [11–13]. By using
more innovative vaginal ring designs and alternative polymer mate-
rials, researchers have demonstrated eﬀective release of relatively hy-
drophilic small-molecule antiviral molecules (e.g. tenofovir [14–17],
tenofovir disoproxil fumarate [18–21], acyclovir [17,22–24], em-
tricitabine [19,20]), peptides (e.g. leuprolide acetate [25], T-1249
[26]), proteins (e.g. HIV glycoprotein gp140 [27], antibodies [28–30]),
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hydrophilic polymers (e.g. carrageenan [31,32]) and metal-containing
actives (e.g. cisplatin [33]; zinc acetate [31,32]).
However, many of these newer ring designs require complex multi-
step manufacturing processes that will likely prove diﬃcult and ex-
pensive to scale. For example, the leuprolide-releasing ethylene vinyl
acetate (EVA) ring described by Kimball et al. comprises ten distinct
manufacturing steps: (i) washing of EVA beads to remove monomeric
vinyl acetate; (ii) vacuum drying of beads; (iii) cryogenic milling of EVA
granules to powder; (iv) preparation of ethanolic solution of EVA and
leuprolide; (v) solvent casting of the ethanolic mixture; (vi) solvent
evaporation; (vii) milling of the EVA/drug mixtures to form a powder;
(viii) extrusion of the leuprolide acetate/EVA granulation mixture; (ix)
pelletization of the mixtures; and ﬁnally (x) manufacture of the rings by
injection molding [25]. The widely reported pod-insert vaginal rings
[17,19,21,23,30,34–36] – comprising multiple individual polymer-
coated drug cores embedded in a ring body, each core connected to the
external environment through a preformed delivery channel – are
similarly complex and time-consuming to manufacture, involving at
least nine distinct steps: (i) compaction of drug powder to form a core;
(ii) drop-coating of cores using a polylactic acid solution; (iii) fabrica-
tion of silicone elastomer ring bodies via injection molding; (iv) crea-
tion of delivery channels by mechanical punching; (v) trimming of
sprue material and ﬂashing; (vi) cleaning of silicone with ethanol to
remove debris from the molding process; (vii) manual placement of a
drug-loaded pod into each cavity; (viii) backﬁlling of the pod cavity
with non-medicated silicone elastomer; (ix) ﬁlling of any unused pod
cavities [17]. There is, therefore, a need for new vaginal ring designs for
sustained/controlled release of hydrophilic or macromolecular drugs
that can be easily manufactured using more conventional and scalable
processes.
5P12-RANTES (MW 7904.8 g/mol) – a fully recombinant chemo-
kine analogue that potently blocks the HIV CCR5 coreceptor – is being
developed as both a vaginal and rectal microbicide for prevention of
sexual transmission of HIV [37–39]. Previous studies have reported
complete protection against vaginal challenge with simian/human im-
munodeﬁciency virus (SHIV) in rhesus macaques [40] and encouraging
pharmacokinetic data in a sheep model following administration of
vaginal gels containing 5P12-RANTES [41]. Unusually for a protein
therapeutic, the high thermal and biological stability [37,39,41], cou-
pled with a scalable low-cost cGMP process for production of clinical
grade material [42], make 5P12-RANTES a viable candidate for for-
mulation in a vaginal ring device.
Here, for the ﬁrst time, we report a new ‘exposed-core’ vaginal ring
design and demonstrate its potential for sustained release of proteins,
ﬁrst using lysozyme as a model protein, and then using 5P12-RANTES
as a potent experimental HIV microbicide. Manufactured from silicone
elastomer and common water-swellable pharmaceutical excipients
using simple, scalable and well-established injection molding technol-
ogies, the ring oﬀers certain advantages over previously reported ring
designs for vaginal administration of hydrophilic and macromolecular
drugs.
2. Materials and methods
2.1. Materials
5P12-RANTES solution (cGMP grade; 6.4mg/mL in 1.7mM acetic
acid; pH 4.0) was supplied to Queen's University Belfast by the Mintaka
Foundation for Medical Research, Geneva Switzerland [42]. 10 and
120 kDa molecular weight hydroxypropylmethylcellulose (HPMC), ly-
sozyme, acetonitrile and triﬂuoroacetic acid (TFA) were purchased
Table 1
Summary characteristics of marketed vaginal rings and rings in clinical development.
Product name vaginal ring type;
polymera
Drug(s) Clinical indication; duration of action Developer Stage
Estring® reservoir; silicone 17β-estradiol estrogen replacement therapy; 90 days Pﬁzer Marketed
Nuvaring® reservoir; EVA etonogestrel and ethinyl
estradiol
combination contraception; 21 days Merck Sharp & Dohme Marketed
Femring® reservoir; silicone 17β-estradiol-3-acetate estrogen replacement therapy; 3months Warner Chilcott Marketed
Progering® matrix; silicone progesterone postpartum contraception; 1 year Population Council Marketed
Fertiring® matrix; silicone progesterone hormonal supplementation and pregnancy
maintenance; 3 months
Population Council Marketed
Ornibel® reservoir; EVA and TPU etonogestrel and ethinyl
estradiol
combination contraception; 21 days Exeltis Healthcare Marketed
Annovera® reservoir; silicone Nestorone® and ethinyl
estradiol
combination contraception; one year Population Council Approved
– matrix; silicone dapivirine HIV prevention; 30 days IPM Undergoing review
– matrix; silicone dapivirine and maraviroc HIV prevention; 30 days IPM Phase I
– matrix; silicone dapivirine and levonorgestrel HIV prevention and contraception; 90 days IPM Phase I
– reservoir; TPU tenofovir HIV and HSV-2 prevention; 90 days CONRAD Phase I
– reservoir; EVA vicroviroc and MK-2048 HIV prevention; 28 days Merck Sharp & Dohme Phase I
– reservoir; silicone ulipristal acetate contraception; 3months Population Council Phase 1/2
a EVA – ethylene vinyl acetate copolymer; TPU – thermoplastic polyurethane.
Fig. 1. Plot of log partition coeﬃcient (logP; experimental or calculated values)
vs. molecular weight for drug molecules in marketed vaginal rings or having
previously been considered for formulation in vaginal rings. Plot symbols inside
the dashed box include estradiol, ethinyl estradiol, etonogestrel, estradiol-3-
acetate, dapivirine, progesterone, levonorgestrel, maraviroc, MIV-150, oxybu-
tynin, segesterone acetate (Nestorone®), norethindrone acetate, ulipristal
acetate, medroxyprogesterone acetate, UC781, danazol, MC1220, CMPD-167,
drosperinone, nomegestol acetate, and vicriviroc. Molecules outside the dashed
box (see labels within the ﬁgure) are those currently being considered for va-
ginal ring formulations and that, due to physiochemical constraints, generally
require novel formulation approaches.
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from Sigma-Aldrich (UK). DDU-4320 silicone liquid rubber was ob-
tained from Nusil Technology (Carpinteria, CA, USA) and the pre-
stained molecular weight marker from Life Technologies (Thermo
Fisher Scientiﬁc, UK). 1× tris/glycine/SDS buﬀer, Laemmli sample
buﬀer and 20% Mini-PROTEAN TGX precast gels were purchased from
Bio-Rad, UK.
2.1.1. Sieving of HPMC material
HPMC powder (molecular weight: 120 kDa) was separated into four
particle size fractions using stacked analytical sieves having 125 μm,
90 μm and 53 μm mesh sizes. HPMC that remained in the 125 μm sieve
was classiﬁed as the> 125 μm fraction, powder that remained in the
90 μm sieve as the 90–125 μm fraction, material in the 53 μm sieve was
designated as 53–90 μm and the material that passed through all sieves
was the<53 μm fraction.
2.1.2. Freeze-drying of 5P12-RANTES
5P12-RANTES solution was freeze-dried to produce a lyophilised
powder. 5P12-RANTES was aliquoted into ﬂat bottomed glass petri
dishes (diameter 200mm) and freeze-dried (AdVantage Pro BenchTop
Freeze Dryer, VirTis, Gardiner, NY, USA) using the following para-
meters: 5 to −40 °C ramp for 1 h followed by an additional freeze for
2 h. The condenser was then set to−50 °C and a chamber pressure of 50
mTorr. Shelf temperature was gradually raised to 20 °C over 27 h, with
a coinciding increase in chamber pressure from 120 to 190 mTorr.
Further details are provided in the supplementary data (Table S1).
2.1.3. Vaginal ring manufacture
Silicone elastomer rings, comprising cores loaded with HPMC and
either lysozyme (a model protein) or lyophilised 5P12-RANTES powder
and with the cores partially exposed to the external environment by an
overmolded silicone elastomer sheath containing one or more discrete
windows, were manufactured using a simple two-step injection molding
process. ¼- or full-length cores (cross-sectional diameter, 4.2 mm) were
ﬁrst manufactured using a temperature-controlled laboratory-scale in-
jection molding machine ﬁtted with a custom mold assembly (Fig. 2).
DDU-4320 addition-cured silicone elastomer kit is comprised of two
parts. Both parts contain a basic silicone formulation, primarily vinyl-
functionalized and hydroxy-terminated poly(dimethyl siloxane)s. Part
A also contains a platinum catalyst and part B contains a hydride-
functionalized poly(dimethyl siloxane) crosslinker which when mixed
react via a hydrosilylation addition reaction. Here, Part A and Part B
DDU-4320 silicone elastomer premixes containing 8.58% w/w lyso-
zyme and 17.2% w/w of 10 kDa or 120 kDa HPMC (bulk,> 125 μm,
90–125 μm, 53–90 μm or < 53 μm particle size) were prepared by
adding weighed quantities of the powdered materials into a screw-cap
polypropylene container, followed by addition of the silicone elastomer
parts, and then mixed using a Dual Asymmetric Centrifuge (DAC) mixer
(30 s, 3000 rpm; SpeedMixer™ DAC 150 FVZeK, Hauschild, Germany)
(Fig. 2A). A and B premixes were then combined in a 1:1 ratio, ac-
cording to the following procedure: (i) equal weights of each premix
were added to a screw-cap polypropylene container to a ﬁnal batch
weight, (ii) the material was hand-mixed for 30 s and then DAC mixed
(15 s at 1500 rpm). The active mix was transferred to a 75 g poly-
propylene SEMCO injection cartridge designed for use with the SEMCO
Model-850 injection system. Full-length ring cores (outer diameter,
54.0 mm) were prepared by injecting the active mix into the heated ring
mold assembly (85 °C) and curing for 3min (Fig. 2B). The resulting
lysozyme-loaded cores were subsequently overmolded with drug-free
DDU-4320 silicone elastomer in a further injection molding step, using
a custom mold assembly designed to introduce 24 circular oriﬁces in
the sheath (Fig. 2C and D3). Rings were subsequently demolded, de-
ﬂashed (where necessary) and stored at ambient temperature until
further testing.
¼-length DDU-4320 silicone elastomer cores containing 8.58% w/w
freeze-dried 5P12-RANTES and 17.2% w/w 120 kDa HPMC (not sieved)
were similarly manufactured and overmolded. Using custom mold as-
semblies, three alternative sheath designs were prepared to expose
diﬀerent fractions of the underlying ¼-length core. The ﬁnal rings
contained a ¼-length core having one or six discrete 3.0mm diameter
circular oriﬁces (Fig. 2 D1 and D2; 9.34 or 56.04mm2 core exposure),
one ¼ core with two large windows (Fig. 2 D4; 210.9 mm2), or two ¼
-length cores with four large windows (see graphical abstract;
421.8 mm2).
2.1.4. Rheological assessment of silicone elastomer mixes
Continuous ﬂow rheology was carried out using an AR 2000
Rheometer ﬁtted with a 40mm diameter steel parallel plate (TA
Instruments, USA) to assess the cure characteristics of the silicone
elastomers mixes, following methods described previously [43,44].
Brieﬂy, samples were applied to the base plate and the steel parallel
plate was lowered to a gap depth of 1000 μm. Excess material was re-
moved before the test. Following a 5min equilibration step ﬂow
rheology was carried out at 21 °C, continuous ramp mode, from
0.01–100 Hz. Storage modulus (G'), loss modulus (G") and tan δ values
were measured as a function of time.
2.1.5. In vitro release testing of vaginal rings
Rings were placed in 15mL of Type 1 water (Millipore Direct-Q 3
UV Ultrapure Water System, Watford, UK) in polypropylene containers
(Synergy Devices Limited, United Kingdom). The containers were
stored in an orbital shaking incubator (37 °C, 60 rpm, 25mm orbital
throw) and the release media were sampled periodically with complete
volume replacement. Samples were stored at 4 °C and the concentra-
tions of 5P12-RANTES measured using HPLC and/or ELISA.
2.1.6. Quantiﬁcation of 5P12-RANTES using HPLC
5P12-RANTES and lysozyme concentrations in the in vitro release
samples were measured using a Waters Alliance e2695 HPLC and UV
2489 detector (Waters, Dublin, Ireland), Empower data handling soft-
ware and an ACE C8 column (ACE 3 μm, C8, 300 Å, 150×4.6mm)
(Aberdeen, UK). 5P12-RANTES analysis was performed using 100 μL
injection volumes, a gradient method comprising mobile phases A
(0.1% TFA in water), B (0.0955% TFA/30% acetonitrile in water) and C
(0.085% TFA/95% acetonitrile in water), and a column temperature of
37 °C. Lysozyme analysis was performed using 10 μL injection volumes,
a gradient method comprising mobile phases A (0.1% TFA in water), B
(0.1% TFA in acetonitrile) and a column temperature of 45 °C. For both
methods, mobile phase ﬂow rate was 1mL/min and detection wave-
length was 280 nm.
2.1.7. Quantiﬁcation of 5P12-RANTES using ELISA
5P12-RANTES concentrations were also quantiﬁed by ELISA using
the Human CCL5/RANTES ELISA kit (R&D Systems, UK, cat no.
DRN00B). Samples were analyzed as per the manufacturer's instruc-
tions and the appropriate dilutions were made to ensure all readings fell
within range of the standard curve of the kit (0.002–2 ng/mL). The
absorbance was measured at 450 nm (EnSpire™ Multimode Plate
Reader, PerkinElmer, USA) with correction at 570 nm to account for
plate imperfections. A four-parameter logistic (4-LP) standard curve
was generated and sample concentrations were calculated relative to it.
Results were subsequently multiplied by the appropriate dilution factor.
2.1.8. Determination of release medium uptake
Ring weights were recorded before and after in vitro release testing.
The rate of swelling of the rings was reported as a percentage increase
in weight relative to the initial weights.
2.1.9. SDS-PAGE
SDS-PAGE was performed using a Mini Protean II Tetra cell (Bio-
Rad Laboratories, USA) using a 1× tris/glycine/SDS buﬀer. Samples
were mixed at a 3:1 ratio with 2× Laemmli sample buﬀer and then wet-
J.W. McBride et al. Journal of Controlled Release 298 (2019) 1–11
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loaded onto a 20% Mini-PROTEAN TGX precast gel alongside a pre-
stained molecular weight marker. Samples were run for 45min, 150 V,
and visualized using Coomassie staining.
2.1.10. Physical characterization and mechanical testing of rings
Batches of rings were manufactured and their mechanical properties
evaluated using a range of custom mechanical tests [45]. The force
required to compress ring devices by 5mm was measured using a
Texture Analyser (TA-XTPlus, Stable Microsystems, UK), ﬁtted with a
30 kg load cell and Texture Exponent (TEE32) 32 software, and using a
custom ring holder. Full ring devices were tested in three diﬀerent or-
ientations due to the asymmetric nature of their designs, with core
inserts being either at the top, side or base during each test. A number
of other tests were performed on the rings, loosely derived from ISO
8009. A static, 28-day compression test was performed by placing rings
into a custom compression jig that compressed them to 25 ± 5% of
their original outer diameter (OD). After 28 days, the rings were re-
moved from the compression jig and allowed to recover for a period of
15–20 s before the percentage recovery of the original ring diameter
was recorded. Rings were subjected to a 1000-cycle compression test by
compressing to 25 ± 5% of their original OD and releasing 1000 times.
Custom ring holders were fabricated, capable of holding multiple rings
simultaneously, for use with the Texture Analyser. An aluminium plate
with multiple rectangular ring holding grooves (7 per plate) was
mounted on the lower ﬁxed platform of the analyser. An upper Perspex
plate with identical grooves, mounted on the upper moveable arm of
the TA (so the centrelines of lower and upper grooves were aligned),
was lowered until it touched the top of the rings so that all rings were
held in a vertical position with slight pre-compression. Generally, rings
(n=6 per formulation) were cyclically compressed from 100% to
25 ± 5% of their original OD, 1000 times at a crosshead speed of
15mm/s. Finally, the degree of twist during compression was recorded.
A custom manufactured twist-tester kept the top of the ring rotationally
ﬁxed while the bottom of the ring was able to rotate freely in a holder
mounted on a low friction bearing. Rings were compressed by lowering
the TA cross-arm so that the distance between the lower ring mount and
the cross-arm was in accordance with diaphragm twist-test parameters
as stated in Annex F of ISO8009:2014. Where ring external diameters
did not correspond with those stated for diaphragm devices, the dis-
tance between the cross-arm and the ring holder was determined by
extrapolation or interpolation using the mean external diameter for
each ring formulation. The degree of twist (angular rotation) of the ring
during compression was indicated by movement of a pointer, attached
to the bottom holder, on an angular scale away from the starting (zero)
position in either a clockwise or anticlockwise direction.
2.1.11. Pharmacokinetic evaluation of 5P12-RANTES vaginal ring in sheep
Two exposed-core vaginal ring formulations – one containing a
single 63.5 mg 5P12-RANTES core and two windows, the other con-
taining two 63.5mg 5P12-RANTES cores and having four windows –
were evaluated for pharmacokinetics in Suﬀolk Cross sheep
(36–37months; 63.0–95.0 kg) at Envigo (Huntingdon, UK). Vaginal
ﬂuid, vaginal tissue and serum concentrations of 5P12-RANTES were
measured during 28-day ring use. The sheep were housed in indoor
pens with wheat straw bedding, and provided with natural light sup-
plemented with overhead ﬂuorescent lighting as necessary and full
fresh air. The animals grazed on ewe and lamb pencil pelleted diet,
were provided good-quality meadow hay ad libitum, and had an un-
restricted water supply. A total of eight sheep were used in the study.
On day 1 of the study, each animal was restrained in a comfortable
standing position and the test ring inserted carefully into the cranial
vagina, using a gloved ﬁnger and a small amount of medical-grade
Fig. 2. Description of the steps required for manufacture of an exposed-core vaginal ring. A – Preparation of silicone elastomer active mix comprising Parts A and B of
the DDU-4320 silicone elastomer, the freeze-dried 5P12-RANTES and hydroxypropyl methylcellulose (HPMC). B – Mold tool for production of ¼- or full-length 5P12-
RANTES cores. C – Cores are placed into custom mold tools having raised pins to position and support the core. Subsequent injection of drug-free silicone elastomer
mix into the molds produces rings having overmolded cores partially exposed to the external environment via oriﬁces in the sheath. The shape and size of the oriﬁces
depends on the mold design. D – Four diﬀerent types of exposed-core vaginal rings were produced: ring D1 contains a single small oriﬁce; ring D2 contains six small
oriﬁces, three on each side of the ring; ring D3 contains 24 small oriﬁces, twelve on each side; ring D4 contains two large window oriﬁces, one on each side. E –
representation of the ring cross-section.
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lubricant gel as appropriate. Strings (medical-grade monoﬁlament su-
ture material) were ﬁtted to the rings before application and the ends of
the tapes left hanging outside the vagina after application. These strings
served as an external visual check that the ring was still in place and
had not been expelled, and aided retrieval of rings at the end of the
study period.
Blood and vaginal ﬂuid were sampled at the following timepoints:
pre-dose, 4 and 24 h, 2, 4, 7, 14, 21, 28 and 35 days post ring insertion.
Blood samples were drawn from the jugular vein and incubated for a
minimum of 60min at room temperature to facilitate clotting.
Subsequently, the samples were centrifuged (1500 × g, 15min) to
separate the serum and then divided and stored at −20 °C in poly-
propylene tubes. Vaginal ﬂuid was sampled using a preweighed Weck-
Cel sponge that was again weighed after ﬂuid uptake. The sponge was
held in place in the vagina for 1min and stored at −20 °C in bor-
osilicate glass tubes. Vaginal tissue biopsy specimens (5mm diameter)
were sampled on day 7, 21 and 35 post ring insertion from the dorsal
aspect of the vagina under local anaesthetic (isoﬂurane and oxygen
were used where necessary). Analgesia was administered 30min prior
to vaginal biopsy specimen collection. Samples were rinsed with RPMI
1640 and weighed prior to freezing at −70 °C. Frozen samples were
submitted for analysis to Envigo's Department of Biomarkers,
Bioanalysis, and Clinical Sciences (Immunoassay). Brieﬂy, all tissue
samples were homogenized in homogenization buﬀer (PBS with 2%
Triton X-100 and protease inhibitor cocktail) at 4 °C and kept on wet ice
at all times. The tissue specimens were placed in a minimum of 3mL of
buﬀer, and the ratio of buﬀer/sample weight was recorded. Samples
were homogenated (GentleMACS dissociator) and centrifuged at 4566
× g for 10min. The supernatant was collected into tubes (Watson la-
belled PP) and placed on wet ice or stored at −70 °C. Analysis was
performed using a human CCL5/RANTES ELISA kit, according to the
manufacturer's instructions. Clinical condition, body weight, and food
consumption were recorded during the study.
3. Results and discussion
Polymeric systems for the sustained release of large molecular
weight therapeutic agents – and particularly proteins – has been a
major topic of interest in the pharmaceutical sciences ﬁeld since the
1970s [46–52]. More recently, delivery systems for sustained release of
proteins have been reported using hydrogels [53,54], injectable bio-
degradable systems [55,56] and electrospun biodegradable ﬁbers [57].
Implantable silicone elastomer systems for the sustained/controlled
release of proteins have also previously been reported, and mostly in-
volve incorporation of high concentrations of one or more water-so-
luble or pore-forming (porosigens) excipients into the silicone matrix
[58–64]. However, a particular diﬃculty with this approach is that the
rings imbibe ﬂuid and swell in proportion to the quantity of excipient
incorporated. Since relatively large quantities of excipient are required
to obtain meaningful release of proteins, the ring devices can often
increase signiﬁcantly in size and weight [58,59]. Clearly, this is im-
practical and unsafe from a clinical perspective. To overcome this dif-
ﬁculty, vaginal ring devices have been reported in which one or more
small drug-loaded module(s) containing the drug and various water-
soluble or water-swellable excipients are manufactured separately and
later inserted into a silicone elastomer ring body containing channels
that act as retainers for the modules [26–28]. In a similar fashion, a
‘ﬂux controlled pump’ capable of 30-day controlled release of the model
macromolecules dextran and insulin to the vaginal mucosa has pre-
viously been reported [65,66]. The pump comprised a compressed
water-soluble polymer pellet compounded with a macromolecular drug
and enclosed in a hard polymer casing containing oriﬁces to allow in-
ﬂux of vaginal ﬂuid and eﬄux of the hydrated contents. The hydration
kinetics and osmotic pressure were controlled through oriﬁce number
and geometry. In order to retain the pump in the vagina without re-
sorting to surgical stitching, the pump was attached to a separate ring-
shaped polyurethane retainer. In this way, the ring retainer is physically
distinct from the drug delivery module. However, both these ap-
proaches have their disadvantages. In the former, there is limited
loading capacity in the relatively small modules for the drug and ex-
cipient (although multiple inserts are possible) and the duration of re-
lease is also constrained. In the latter, the design is inelegant and im-
practical for use in women. The ring design described in this current
study successfully builds on the principles and concepts described in
these previous studies while addressing the manufacturing and design
obstacles.
3.1.1. Rheological assessment of the active silicone mixes
The protein-loaded cores of the rings were manufactured by injec-
tion molding of liquid silicone elastomer mixes containing either lyso-
syme or lyophilised 5P12-RANTES and HPMC. The viscosities of these
mixes depend upon the viscosity of the silicone elastomer used and the
concentration and particle size of the incorporated drugs and ex-
cipients. The liquid silicone rubber – immediately following mixing of
all components and up to the point of molding – can be considered as an
inelastic non-Newtonian liquid, the viscosity of which is important for
injection into the molds. Rheological measurement of the shear visc-
osity as a function of increasing shear rate is reported in Fig. 3 for blank
DDU-4320 and four formulations containing loadings of HPMC ranging
from 0 to 22.5% w/w. As the loading of HPMC is increased in the
formulations, there is a reduction in the shear rate required to observe
shear thinning in the liquid silicone continuous phase, indicating the
particles of HPMC are not interacting with the silicone. Additionally,
the eﬀect of HPMC loading on viscosity is signiﬁcantly higher at lower
shear rates where the ﬂow is Newtonian compared to shear rates
Fig. 3. Mean shear viscosity (± SD; n=3) of DDU4320 liquid silicone rubber
homogenous mastermix formula-tions at a shear rate range of 0.01–100 Hz (A)
and at a shear rate of 1.065 Hz (B). Formulations contained 0%, 8.6%, 17.2%,
and 22.5% w/w HPMC loading and 8.6% w/w lysozyme. The blank formulation
consisted of 100% w/w DDU4320.
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of> 10, where the curves begin to become parallel, follow a power-law
behaviour and show similar viscosities across the formulations. The
manual process used to inject the silicone into the mold cavity produces
a low shear rate at which the mixture is observed to be in Newtonian
ﬂow and the particle loading is critical to viscosity. In this study, where
rings were manufactured via a manual injection molding process, the
maximum HPMC concentration that could practically be injected was
17.2% w/w. In larger scale LSR molding equipment having a hydraulic
piston for injection of the silicone mix, typical shear rates are in the
order of 20–700 Hz within the injection unit, and can increase up to
10,000 Hz within the mold tool depending on the geometry of the
runners and gates used. These higher shear rates could facilitate the use
of HPMC loadings greater than those possible using manual injection,
due to the shear thinning nature observed for the formulations ana-
lyzed.
3.1.2. Ring manufacture
Using custom mold assemblies containing protruding pins for
Table 2
Characteristics of vaginal ring formulations containing either the model protein lysozyme or the experimental CCR5 inhibitor 5P12-RANTES.
Vaginal ring formulation
number
Drug (loading in mg) Core length Characteristics of HPMC in core No. and size of
oriﬁces
Surface area of core exposure
(mm2)
HPMC MW
(kDa)
HPMC
loading (w/w
%)
HPMC
particle size
(μm)
1 – full length
(blank)
– – – 24 small 224.2
2 Lysozyme (234.23) full length 120 8.6 bulk 24 small 224.2
3 Lysozyme (234.23) full core 120 17.2 bulk 24 small 224.2
4 Lysozyme (234.23) full core 10 17.2 bulk 24 small 224.2
5 Lysozyme (234.23) full core 120 17.2 < 53 24 small 224.2
6 Lysozyme (234.23) full core 120 17.2 53–90 24 small 224.2
7 Lysozyme (234.23) full core 120 17.2 90–125 24 small 224.2
8 Lysozyme (234.23) full core 120 17.2 < 125 24 small 224.2
9 5P12-RANTES
(63.49)
¼ core 120 17.2 bulk 1 small 9.3
10 5P12-RANTES
(63.49)
¼ core 120 17.2 bulk 6 small 56.0
11 5P12-RANTES
(63.49)
¼ core 120 17.2 bulk 2 large 210.9
12 5P12-RANTES
(126.98)
¼ core × 2 120 17.2 bulk 4 large 421.8
Fig. 4. Eﬀect of HPMC loading (120 kDa) on drug release (A) and ring swelling (B) on 24 oriﬁce full core rings containing lysozyme. The Eﬀect of HPMC molecular
weight (C) and HPMC (120 kDa) particle size (D) on drug release from full core vaginal rings into water, 37 °C. Mean ± SD, n=3.
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location of the core component, vaginal rings with oriﬁces in the sili-
cone elastomer sheath that partially expose the underlying protein
+excipient loaded silicone elastomer core were readily manufactured
in two steps via conventional injection molding technology (Fig. 2).
Rings were manufactured having 1, 6 or 24 small circular oriﬁces or
two large windows, each giving rise to diﬀerent surface areas of ex-
posure of the underlying core (Table 2). Further modulation of the
surface area of exposure could be readily achieved by design and fab-
rication of mold assemblies with diﬀerent pin conﬁgurations.
3.1.3. In vitro release of model protein lysosome
Cumulative lysosome release vs. time plots for exposed-core vaginal
rings (24 small circular oriﬁces) containing 224.2mg lysozyme in a full-
length silicone elastomer core modiﬁed with either 0, 8.6 or 17.2% w/w
bulk HPMC powder (ring formulations 1–3, Table 2) are presented in
Fig. 4A. For the two lower HPMC concentrations, lysosome release rates
were similar with a total of ~5mg released over the 30-day period. A 3-
fold increase in lysosome release (~15mg after 30 days) was obtained
by increasing the HPMC loading to 17.2% w/w. It is assumed that re-
latively high HPMC concentrations are needed to promote suﬃcient
penetration of release medium into the silicone cores, resulting in the
formation of interconnected aqueous pores and channels in the silicone
elastomer and a concomitant increase in the drug release rate, as has
been reported previously for other excipient-modiﬁed silicone elas-
tomer drug delivery systems [26,58,63]. The ring weights increase over
the course of the in vitro release study (Fig. 4B) due to imbibing of the
release medium into the ring, are dependent upon the HPMC content,
and correlate with the in vitro release data (Fig. 4A). The molecular
weight (Fig. 4C) and the particle size (Fig. 4D) of the HPMC excipient
incorporated into the silicone elastomer core of the vaginal ring also
signiﬁcantly inﬂuenced the release of lysozyme. A 120 kDa HPMC
material increased release twofold compared with a 10 kDa HPMC
(Fig. 4C), while increasing HPMC particle size from<53 μm to>
125 μm produced a 7-fold increase in lysosome release, reﬂecting si-
milar trends reported previously for release of the model protein drug
interferon from simple silicone elastomer matrices [58].
3.1.4. In vitro release of 5P12-RANTES
Unlike the lysosome release study, limited availability of 5P12-
RANTES constrained in vitro release testing to rings with only ¼-length
cores. HPLC-generated data for in vitro cumulative release of 5P12-
RANTES from ¼-core rings having 1 oriﬁce, 6 oriﬁces or 2 large win-
dows (Formulations 9–11, respectively; Table 2) are presented in
Fig. 5A, and demonstrate that increasing the surface area of core ex-
posure to the release medium leads to increased 5P12-RANTES release.
For the two-window ring, almost 300 μg 5P12-RANTES was released on
Day 1, with 921 μg (equivalent to 1.45% of the initial 63.5mg loading)
released in total over the 28-day test period. For comparison, the lead
candidate 25mg dapivirine (DPV) ring – a matrix-type ring which
successfully completed Phase III clinical testing in 2016 [8,9] and is
currently undergoing regulatory review – provides Day 1 in vitro DPV
release of ~ 600 μg and total cumulative release of ~4500 μg (18% of
the initial 25mg loading), reﬂecting the much greater surface area for
drug release oﬀered by the traditional matrix-type ring format and the
greater permeability of DPV in the silicone elastomer system due to its
physicochemical properties (Fig. 1). In comparison to VRC01 drug re-
lease from pod-type IVRs, 5P12-RANTES release is much lower. This is
likely related to the diﬀerences in ring formulation. 5P12-RANTES drug
release is dependent on water imbibing and swelling the HPMC com-
ponent which subsequently facilitates the dissolution and release of
5P12-RANTES from the silicone elastomer core. It is likely that drug
release is constrained by the viscosity and polymeric nature of the core.
Conversely, as polymeric excipients are not used in pod-ring design the
drug, e.g. VRC01, is in a more readily available state. Two methods to
improve the drug release would be to increase the HPMC loading per-
centage of the core or use a half- or full- core ring. Indeed, in the PK
study here we included a half-core arm with the aim to further enhance
drug release. Fig. 5B shows in vitro 5P12-RANTES release data for the 2-
window ring (Formulation 11, Table 2) as measured by ELISA. The
values are broadly similar to those measured by HPLC (Fig. 5A), and
conﬁrm that that 5P12-RANTES eﬀectively maintains its stability
during ring manufacture such that antibody binding, and thus con-
formational integrity, is retained. Further evidence that 5P12-RANTES
is released intact from the vaginal rings and that it remains stable in the
ring upon storage at 4 °C for 3months is provided by the SDS-page data
presented in Fig. S1 (Supplementary Information). In vitro 5P12-
RANTES release data, measured both by HPLC and ELISA, after 3-
month storage is presented in Fig. S2 (Supplementary Information),
again demonstrating good stability of the protein and reproducible re-
lease rates. It is anticipated that there would be no detrimental eﬀects
to the rings at room temperature, and potentially higher environmental
temperatures, over time as it was previously reported that 5P12-
RANTES is stable following incubation at 55 °C for 24 h and 40 °C for
7 days [37]. However, this requires further investigation.
Fig. 5. Cumulative release of 5P12-RANTES from two large window, six oriﬁce
and one oriﬁce exposed-core vaginal rings as measured by HPLC (A) and cu-
mulative release of 5P12-RANTES from two large window exposed-core vaginal
ring as measured by ELISA (B). Swelling of the rings was measured by recording
as percentage weight change (C). Samples were incubated in water during the
study, 37 °C, mean ± SD, n=3.
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3.1.5. Mechanical testing
Fig. 6C reports mean forces to produce 5mm compression in ¼-core
ring devices. A decrease in force was observed from 0.19 to 0.17 N as
the number of oriﬁces increased from one to six. For the dual large
window ring, the force required to compress by 5mm was between that
for one or six oriﬁce designs at 0.18 N. These values were signiﬁcantly
lower than those observed for commercial rings, Fertiring® and Pro-
gering® at 0.89 and 1.24 N respectively indicating that the sheath ma-
terial in the RANTES ring is of a lower modulus. The orientation of the
ring during 5mm compression did not produce statistically signiﬁcant
diﬀerences in the mean force value (Fig. 6D), suggesting that the clin-
ical positioning of the ring device would not be critical from a user
comfort perspective.
Similar results were observed for rings undergoing either static, 28-
day compression or dynamic, 1000-cycle compression testing. In both
cases, rings recovered to at least 90% of their original outer diameter
following removal from the corresponding jig and there was no evi-
dence of damage at the core/membrane oriﬁce interface, or at any
other points throughout the devices. There was no observable correla-
tion between the ring oriﬁce geometries and the degree of mean
Fig. 6. Ring following 28-day static deformation testing, the
one oriﬁce ring pictured recovered 90–100% of its outer
diameter upon removal from the jig (A); ring prior to com-
mencing 5mm compression test (B); 5 mm compression
testing of one oriﬁce (1O), six oriﬁce (6O), two large windows
(LW) and a comparator 25mg dapivirine ring manufactured
in-house (C); 5mm compression testing of rings in various
orientations: T – top, with the core segment positioned up-
ward toward the probe (as pictured in b); S – side, with core
segment facing out from the instrument; B – bottom, with the
core positioned downwards furthest from the probe (D).
Fig. 7. Concentrations of 5P12-RANTES measured in
the vaginal ﬂuid (A) and biopsied vaginal tissue (B)
of Suﬀolk Cross sheep during and after 28-day va-
ginal ring use. Black plot symbols show data for
¼-core rings with two large windows; unﬁlled plot
symbols show half core rings with four large win-
dows. Plot symbols represent mean ± standard de-
viation of four replicates.
Table 3
Statistical pharmacokinetic parameters for 5P12-RANTES measured in sheep vaginal ﬂuid and vaginal tissue during and after 28-day use of exposed-core vaginal
rings. Cmax and AUC0 –last values are presented as mean ± SD of four replicates. Tmax values are presented as the medians and ranges of four replicates.
Vaginal ﬂuid Vaginal tissue
5P12-RANTES vaginal ring formulation number (see Table 2) Cmax
(μg/g)
Tmax
(days)
AUC0-last
(μg.day/g)
Cmax
(ng/g)
Tmax (days) AUC0-last
(μg.day/g)
11 19.6 ± 27.5 1, 0.17–4 53.3 ± 37 149 ± 176 14, 7–35 1.5 ± 1.4
12 27.1 ± 22.4 0.58, 0.17–7 117.0 ± 54 1233 ± 1980 7, 7–21 11.9 ± 2.0
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angular deviation recorded during twist tests. Critically, there were no
failure modes observed in any of the devices during any of the me-
chanical tests.
3.1.6. Sheep pharmacokinetics
No clinical signs were observed throughout the study and all rings
remained in place for the 28-day treatment period. The serum con-
centrations of 5P12-RANTES were consistently below the limit of
quantiﬁcation (< 70.4 pg/mL), unlike those measured previously for
5P12-RANTES vaginal gels [41]. 5P12-RANTES was detected in vaginal
ﬂuid and vaginal tissue at all sampling timepoints post-dosing for both
the single ¼-core ring and the double ¼-core ring (Formulations 11 and
12, respectively; Fig. 7). For these rings, vaginal ﬂuid concentrations of
5P12-RANTES peaked (Cmax) within 24 h at 19.6 and 27.1 μg/g, re-
spectively, followed by steadily declining concentrations thereafter. By
Day 28 (day of ring removal), 5P12-RANTES concentrations had de-
clined to 8.0 and 34.3 ng/g, respectively (Fig. 7). One week after ring
removal (Day 35), 5P12-RANTES was still detectable in vaginal ﬂuid,
albeit at signiﬁcantly decreased levels (0.32 and 4.6 ng/g, respectively).
Pharmacokinetic statistical parameters Cmax, Tmax and AUC0-last are
presented in Table 3 for the vaginal ﬂuid data. The rate (Cmax) of local
exposure of female sheep to 5P12-RANTES increased with increasing
dose over the dose range 63.49–126.98mg. However, the increases
were slightly less than the proportionate dose increment. At the highest
dose level (126.98 mg), the Cmax values were 31% lower than those
values predicted from a linear relationship. The extent (AUC0-last) of
local exposure of female sheep to 5P12-RANTES increased approxi-
mately proportionately (AUC ratio 1:2.1) with increasing dose over the
dose range 63.5–127mg. Vaginal tissue concentrations of 5P12-
RANTES during the period of ring use ranged between 32 and 135 and
260–1220 ng/g for vaginal rings containing low (63.49 mg) and high
(126.98mg) initial loadings of 5P12-RANTES, respectively (Fig. 7B).
Overall, the 5P12-RANTES concentrations measured in vaginal ﬂuid
and tissue are at least 50 and up to 50,000 times the reported 18 pM
(0.142 ng/g) in vitro IC50 value [42].
Unsurprisingly, pharmacokinetic concentrations of 5P12-RANTES
obtained with these sustained release vaginal rings were signiﬁcantly
lower than those reported previously for aqueous vaginal gel formula-
tions in the sheep model, where vaginal ﬂuid concentrations declined
from a high of 106 to 107 ng/g at 1 h and 102 to 104 ng/g at 96 h post
dosing and vaginal tissue concentrations ranged from 105 to 106 ng/g at
12 h post dose [41].
4. Conclusions
This new, simple to manufacture, vaginal ring design – comprising
one or more drug-loaded cores exposed to the external environment via
oriﬁces or windows in the overmolded sheath – has demonstrated po-
tential for sustained release of the model protein lysosome and the
antiretroviral protein 5P12-RANTES, and presumably might also be
useful for release of other macromolecular drugs. The incorporation of
relatively high concentrations of the hydrophilic pharmaceutical ex-
cipient HPMC into the silicone elastomer cores enhances the inﬂux of
release medium, thereby signiﬁcantly enhancing the release rate of the
incorporated protein.
The ring design also lends itself to practical incorporation of addi-
tional drug substances, most notably other antiretrovirals to produce a
combination microbicide product and/or a contraceptive steroid to
produce a long-acting MPT product. For example, in addition to in-
clusion of 5P12-RANTES in the core, incorporation of DPV and/or le-
vonorgestrel (LNG) into the sheath component would likely provide
similar in vitro and in vivo release characteristics as the current 25mg
DPV Ring-004 or the DPV+ LNG currently being evaluated in the clinic
[8,9,67,68]. In this way, novel combination antiretroviral vaginal rings
could be considered, incorporating and releasing drugs having very
diﬀerent physicochemical properties.
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